Lead Therapeutic Design will encompass design and synthesize of drug molecules for chemical and biological characterization. Medicinal chemistry and computer-assisted molecular design along with state-of-the-art synthetic approaches will provide novel drug molecules. Novel approaches will be utilized to develop genetic therapies, as well as, peptide and antibody based therapies.
Peptoid library synthesis for selected protein targets
The Preclinical Testing will involve assessment of novel drug molecules including genetic, peptide, and antibody-based therapies in cell-based and animal disease models. Expertise in cardiovascular disease, cancer, neuroscience, and infectious diseases will provide advice and assistance with evaluating novel drugs and therapeutic approaches.
Evaluating two novel small molecules in kidney and cardiovascular diseases
Evaluating novel small molecules in inflammatory disease
Based on preclinical data in cancer disease models we are providing advice and assistance with going forward with repositioning a drug for clinical trials
The Pharmaceutical Optimization will include the evaluation of pharmacokinetic properties and potential toxicity of drug candidates. Biological fluid analysis will quantify drug concentrations using standard assay techniques and state-of the-art mass spectrometry. Biomarker identification will validate and quantify biomarkers for target engagement, proof-of concept, efficacy and safety. This information will be used to refine the pharmaceutical properties of drug molecules and facilitate optimization of the drug candidates.
- Determining pharmacokinetic profile of novel small molecule targeting arachidonic acid pathway
- Determining ability of a novel small molecule to cross the blood brain barrier